retatrutide phase 2 trial duration weight loss results of triple receptor agonist in #obesity at #ADA2023 strong reduction and improvement in metabolic outcomes . Full paper available now @NEJM Size:15mg/30ml GLP-1 receptor agonist dosing Lunakai Health

retatrutide phase 2 trial duration weight loss results of triple receptor agonist in #obesity at #ADA2023 strong reduction and improvement in metabolic outcomes . Full paper available now @NEJM Size:15mg/30ml GLP-1 receptor agonist dosing Lunakai Health

GLP-1 receptor agonist dosing frequencies

The most significant published evidence to date comes from a phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023, which evaluated retatrutide across multiple doses in adults with obesity

Lunakai Health

Size:15mg/30ml

Imagining a successful, comfortable injection before you begin primes your nervous system for that outcome